Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Undecaprenyl pyrophosphate synthase (UPPS) is a key enzyme in the biosynthesis of isoprenoid lipids, catalyzing the formation of undecaprenyl pyrophosphate (UPP), an essential lipid carrier in peptidoglycan synthesis and cell wall assembly in Gram-positive bacteria such as Enterococcus faecalis. UPPS has emerged as a promising antibiotic target because it is essential for bacterial viability and differs significantly from human enzymes, allowing for selective drug targeting. Inhibiting EfaUPPS leads to disruption of cell wall biosynthesis, making bacteria susceptible to lysis. Several classes of small molecule inhibitors are being explored to target UPPS for the development of new antibacterial agents, especially against drug-resistant pathogens.
Enzyme inhibition (inhibitors block the synthesis of undecaprenyl pyrophosphate, leading to cell wall synthesis arrest)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Undecaprenyl pyrophosphate synthase (Enterococcus faecalis) (EfaUPPS).